J Oncol Pharm Pract 2022 Jun 12;28(4):983-985. Epub 2022 Jan 12.
146995Ankara Oncology Training and Research Hospital, Department of Hematology and Bone Marrow Transplantation Center, University of Health Sciences, Ankara, Turkey.
Introduction: Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic cell transplantation (HCT). In the treatment of chronic GVHD, skin directed therapy, systemic corticosteroids, calcineurin inhibitors (such as cyclosporine (CsA) and tacrolimus), rituximab, mycophenolate mofetil (MMF), extracorporeal photopheresis (ECP) and ruxolitinib are used.
Case Report: We present an 18 year old male with Philadelphia chromosome positive acute B lymphoblastic leukemia, treated with allogeneic HCT from a full matched sibling donor. Read More